{"id":516404,"date":"2021-07-22T08:18:02","date_gmt":"2021-07-22T12:18:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/"},"modified":"2021-07-22T08:18:02","modified_gmt":"2021-07-22T12:18:02","slug":"nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/","title":{"rendered":"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology"},"content":{"rendered":"<h2>\nReal World Evidence Confirms Effectiveness and Ease of Use of UroShield<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>Elmsford, NY, July  22, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Q6y1rbIP6zZ7V94diCq57g9P4hJxvYZDdPWlQMETUQixVyzEOiPDjkBXtV5MnYoin3L0w31FVyMWNz5C-aRGPiFRrRI_1w0dGre3Ravdp5E=\" rel=\"nofollow noopener\" target=\"_blank\"><b>NanoVibronix, Inc<\/b><\/a>.,<strong> (NASDAQ: NAOV), a medical device company that produces the UroShield\u00ae and PainShield\u00ae Surface Acoustic Wave (\u201cSAW\u201d) Portable Ultrasonic Therapeutic Devices, today announced that <i>The Journal of Medical &amp; Surgical Urology<\/i> is publishing an article with overwhelmingly positive findings from a study of patients that used its UroShield in real world settings.<\/strong><\/p>\n<p>\n        <strong>\u201cThis independent study is further proof of the effectiveness and applicability of our UroShield device in reducing the incidence of urinary tract infections and the pain and discomfort caused by urinary catheters,\u201d stated Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. \u201cAs we would expect, the patient experiences in the study were statistically significant, with all responding patients reporting that our device was simple, easy to use and materially benefitted them. The patient experiences were so profoundly positive that 100% of the study\u2019s participants are continuing to use the device following the conclusion of the study.\u201d <\/strong>\n      <\/p>\n<p>\n        <strong>Murphy added, \u201cImportantly, the study was conducted in real world settings, including private residences and long-term care facilities. Study participants, who often relied on family members and other assistants, achieved positive outcomes without the benefit of trained clinicians and skilled care givers, reinforcing our assertion of the ease of use of the UroShield device.\u201d <\/strong>\n      <\/p>\n<p>\n        <strong>For the study, 23 patients with reoccurring UTIs were offered to use UroShield for a minimum period of 12 weeks. Objective and subjective measures of improvement were recorded every week, including the number of UTIs, antibiotic treatment, catheter blockage and changes, bladder washout, hospitalizations or nurse visits due to UTIs, level of pain, sleep and mobility. In the findings, patients reported a significant decrease in the number of UTIs and antibiotic treatment, had fewer catheter blockages and catheter changes and pain was reduced significantly by the end of the study.\u00a0 \u00a0\u00a0\u00a0\u00a0<\/strong>\n      <\/p>\n<p>\n        <strong>Researchers at Coventry University concluded that \u2018UroShield reduced the number of UTIs, catheter blockages and changes, and consequently the need for antibiotics. Patients reported the device is easy to use, were related to little to no pain, and overall improved patients\u2019 well-being and mobility.\u2019 The researchers suggest that the device should be considered as an appropriate treatment in long-term persistent UTIs.<\/strong>\n      <\/p>\n<p>\n        <strong>The peer reviewed publication\u00a0 has been submitted to the National Institute for Clinical Excellence (NICE) as further clinical evidence towards UroShield achieving NICE Guidance.<\/strong>\n      <\/p>\n<p>\n        <strong>A link to the complete article will be made available on the company\u2019s website at: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=neGOSPf0dBkW5BLn6qN3HVo4v4_OAQAp5VfKdebZh2hStTGJt1dOHNOx6eoB1HkBpefW_xUbxwcKmUqts0zteCTQ36h0s0V_nm7B-6VbBdg=\" rel=\"nofollow noopener\" target=\"_blank\">nanovibronix.com.<\/a>\n      <\/p>\n<p>\n        <strong>About NanoVibronix, Inc.<\/strong>\n      <\/p>\n<p>\n        <strong>NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company\u2019s primary products include PainShield\u00ae and UroShield\u00ae, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com.<\/strong>\n      <\/p>\n<p>\n        <strong>Forward-looking Statements<\/strong>\n      <\/p>\n<p>\n        <strong>This press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential\u201d or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control, and cannot be predicted or quantified, and include, among others, statements regarding the completion of the public offering, the satisfaction of customary closing conditions related to the public offering and the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) the geographic, social and economic impact of COVID-19 on the Company\u2019s ability to conduct its business and raise capital in the future when needed, (ii) market acceptance of our existing and new products or lengthy product delays in key markets; (iii) negative or unreliable clinical trial results; (iv) inability to secure regulatory approvals for the sale of our products; (v) intense competition in the medical device industry from much larger, multinational companies,; (vi) product liability claims; (vii) product malfunctions; (viii) our limited manufacturing capabilities and reliance on subcontractor assistance; (ix) insufficient or inadequate reimbursements by governmental and\/or other third party payers for our products; (x) our ability to successfully obtain and maintain intellectual property protection covering our products; (xi) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xii) our reliance on single suppliers for certain product components, (xiii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiv) our conducting business in foreign jurisdictions exposing us to additional challenges, such as, e.g., foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and\/or economic instabilities in specific jurisdictions; and (xv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (SEC), including the Company\u2019s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s web site at: http:\/\/www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.<\/strong>\n      <\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/97893548-e425-4ea5-904b-7813fad24eaa\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Brian Murphy\r\nNanoVibronix, Inc.\r\n630-338-5022\r\nbmurphy@nanovibronix.com\r\n\r\nBrett Maas\r\nHayden IR, LLC\r\n646-536-7331\r\nbrett@haydenir.com\r\n<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Real World Evidence Confirms Effectiveness and Ease of Use of UroShield Elmsford, NY, July 22, 2021 (GLOBE NEWSWIRE) &#8212; NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield\u00ae and PainShield\u00ae Surface Acoustic Wave (\u201cSAW\u201d) Portable Ultrasonic Therapeutic Devices, today announced that The Journal of Medical &amp; Surgical Urology is publishing an article with overwhelmingly positive findings from a study of patients that used its UroShield in real world settings. \u201cThis independent study is further proof of the effectiveness and applicability of our UroShield device in reducing the incidence of urinary tract infections and the pain and discomfort caused by urinary catheters,\u201d stated Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. \u201cAs we would expect, the patient experiences &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516404","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Real World Evidence Confirms Effectiveness and Ease of Use of UroShield Elmsford, NY, July 22, 2021 (GLOBE NEWSWIRE) &#8212; NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield\u00ae and PainShield\u00ae Surface Acoustic Wave (\u201cSAW\u201d) Portable Ultrasonic Therapeutic Devices, today announced that The Journal of Medical &amp; Surgical Urology is publishing an article with overwhelmingly positive findings from a study of patients that used its UroShield in real world settings. \u201cThis independent study is further proof of the effectiveness and applicability of our UroShield device in reducing the incidence of urinary tract infections and the pain and discomfort caused by urinary catheters,\u201d stated Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. \u201cAs we would expect, the patient experiences &hellip; Continue reading &quot;NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T12:18:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology\",\"datePublished\":\"2021-07-22T12:18:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/\"},\"wordCount\":1013,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/\",\"name\":\"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=\",\"datePublished\":\"2021-07-22T12:18:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/","og_locale":"en_US","og_type":"article","og_title":"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology - Market Newsdesk","og_description":"Real World Evidence Confirms Effectiveness and Ease of Use of UroShield Elmsford, NY, July 22, 2021 (GLOBE NEWSWIRE) &#8212; NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield\u00ae and PainShield\u00ae Surface Acoustic Wave (\u201cSAW\u201d) Portable Ultrasonic Therapeutic Devices, today announced that The Journal of Medical &amp; Surgical Urology is publishing an article with overwhelmingly positive findings from a study of patients that used its UroShield in real world settings. \u201cThis independent study is further proof of the effectiveness and applicability of our UroShield device in reducing the incidence of urinary tract infections and the pain and discomfort caused by urinary catheters,\u201d stated Brian Murphy, Chief Executive Officer of NanoVibronix, Inc. \u201cAs we would expect, the patient experiences &hellip; Continue reading \"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T12:18:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology","datePublished":"2021-07-22T12:18:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/"},"wordCount":1013,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/","name":"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=","datePublished":"2021-07-22T12:18:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NTExMCM0MzEwMTMyIzIyMDkwODk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nanovibronix-announces-publication-of-compelling-study-results-for-uroshield-in-the-journal-of-medical-surgical-urology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NanoVibronix Announces Publication of Compelling Study Results for UroShield in The Journal of Medical &amp; Surgical Urology"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516404"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516404\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}